Land of Leather
REDUCERetailer Land of Leather has published its maiden annual results in line with forecasts and is seemingly expanding fast.
The group reckons it is the second largest retailer of leather sofas, with approximately 6.2% of the UK sofa market and 11% of the leather sofa market. Finance director Clive Hatchard believes LoL’s sofas are 30-40% cheaper than the competition, with 90% of products sourced form the Far East (up from 80% last time). He has no worries about leather falling out of favour as a sofa covering, as ‘we’re not about fashion, we sell to the mass market and families’.
LoL is looking to take advantage of the vacuum in the sofa space resulting from the exit of a number of furniture foes and the 8.6% growth in the leather sofa market (fabric sofas are growing at 5.6%). 12 new stores were opened in the year, giving a total of 72, and the store roll-out is accelerating at full pelt. Hatchard says four units have been opened in the last three weeks, six are due to open in the next fortnight and ten more are expected in the year to July 2007.
In the 12 months to April, LoL lifted pre-tax profits 6% to £11.3m on revenues raised 24% to £193.9m. Underlying like-for-like growth was around 4.5% and gross profit margin stood at 41.5%, up 150 basis points.
Broker Seymour Pierce forecasts 23.4p and 25.4p of earnings from £17.5m and £19m profits for the next two years. On those figures the shares trade on p/e ratios of 10.8 for 2007 and 9.9 for 2008. However, the shares have almost doubled in the last eight months or so. If you're sitting on healthy gains, take some profits.
- Reduce text size Decrease text size
- Increase text size Increase text size
- Print article Print
- Share this article Share
- Email article to a friend Email
Market cap: £128.1m
PE Forecast: 10.8
Share price: 252p
Subscribe today
More breaking news stories.
More extended feature articles.
And a depth of analysis you
can't find anywhere else.
Advertisement
VCT Report 2010
VCT Report 2010 uncovers the money available
for investment in every single VCT, helping you get one step ahead in the race to attract funding for your unquoted, AIM-listed or PLUS-quoted
company.
Order VCT Report 2010 today using this online form
Cash Shells Directory 2010
A comprehensive overview of cash shells on AIM and PLUS, companies that have become a significant feature on the market landscape. For more information and to order, click here or contact our marketing team on 020 7250 7056.
Coverage of AIM, techMARK and PLUS Markets
Informative features and research on fast-growing companies, small-cap and growth stocks, penny shares, stock market tips and share recommendations, directors' dealings, company news and analysis, new issues and upcoming IPOs.
Take control of your investments
A full year's subscription to What Investment magazine for £19.95, a whopping 58% off. Get the latest news, features and expert advice on ISAs, Investment Trusts and Funds, SIPPS, Investing for Children and much much
more. Find out more here.
The Financial Times Guide to Personal Tax
is the definitive and most up-to-date guide to completing your self-assessment tax return, making sure that you get it right and on time, and showing how you can save tax. For more information and to order, click here or contact our marketing team on 020 7250 7056.
The AIM Guide Spring 2010
The new, fully updated AIM Guide is now available to buy for only £49.95 (saving you £30).
A 'must-have' for any serious investor or professional interested in the market for young, fast-growing companies. Order your copy today Hurry, as offer ends soon!
Share recommendations and small-cap stock picks
Small-cap and growth company share recommendations on AIM- and PLUS-listed companies. Latest analysts' stock tips and advice on which are the best shares to buy on London's junior stock markets.
Popular Recommendations
Advertisement
Latest Recommendations
Delcam 01/09/2010
Delcam, the international seller of CAD/CAM software to the engineering, aerospace and healthcare sectors among others, is a cash-generative small-cap seeing recovery in its markets.
Antisoma 01/09/2010
Bombed-out biotech play Antisoma is hoping two of its drugs will lead to good fortune after experiencing disaster with lung cancer treatment ASA404.
GW Pharmaceuticals 31/08/2010
GW Pharmaceuticals has won approval from Health Canada for its cannabis-based Sativex product to treat spasticity caused by Multiple Sclerosis.
Sectors
